- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Acute myeloid leukaemia (AML)
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1664KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 499KB)
Gemtuzumab ozogamicin – November 2021
Gemtuzumab ozogamicin: Powder for Injection 5 mg; Mylotarg®
Last updated
4 March 2022